Suppressor of cytokine signaling-3 (SOCS-3) and a deficit of serine/threonine (Ser/Thr) phosphoproteins involved in leptin transduction mediate the effect of Fructose on rat liver lipid metabolism

Hepatology

Volumn 48, Issue 5, 2008, Pages 1506-1516

  Vilà, Laia ^a,b   Roglans, Núria ^a,b   Alegret, Marta ^a,b   Sánchez, R María ^a,b   Vázquez Carrera, Manuel ^a,b   Laguna, Juan Carlos ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; CERAMIDE; FRUCTOSE; JANUS KINASE 2; LEPTIN; LEPTIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHOPROTEIN; PHOSPHOPROTEIN PHOSPHATASE 2A; SERINE; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; THREONINE; TRANSCRIPTION FACTOR FKHR; ADENINE PHOSPHORIBOSYLTRANSFERASE; ADIPONECTIN; GLUCOSE; PHOSPHOSERINE; PHOSPHOTHREONINE; SOCS3 PROTEIN, RAT; SUPPRESSOR OF CYTOKINE SIGNALING;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; FATTY ACID OXIDATION; FATTY LIVER; HYPERLEPTINEMIA; HYPERTRIGLYCERIDEMIA; LIPID METABOLISM; LIVER METABOLISM; MALE; METABOLIC DISORDER; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; LIVER; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; PHYSIOLOGY; POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ADENINE PHOSPHORIBOSYLTRANSFERASE; ADIPONECTIN; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; ENZYME ACTIVATION; FRUCTOSE; GLUCOSE; LEPTIN; LIVER; LIVER NEOPLASMS; MALE; PHOSPHOPROTEINS; PHOSPHOSERINE; PHOSPHOTHREONINE; POLYMERASE CHAIN REACTION; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 56149125083     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22523     Document Type: Article

References (44)

1. Elliott SS, Keim NL, Stern JS, Teff K, Havel PJ. Fructose, weight gain, and insulin resistance syndrome. Am J Clin Nutr 2002;76:911-922.
2. Isomaa B, Almgreen P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-689.
3. Hellerstein MK. Carbohydrate-induced hypertriglyceridemia: Modifying factors and implications for cardiovascular risk. Cur Opin Lipidol 2002; 13:33-40.
4. Parks EJ, Hellesrstein MK. Carbohydrate-induced hypertriacylglycerolemia: Historical perspective and review of biological mechanisms. Am J Clin Nutr 2000;71:412-433.
5. Roglans N, Vilà L, Alegret M, Sánchez RM, Vázquez-Carrera M, Laguna JC. Impairment of hepatic STAT-3 activation and reduction of PPARα activity in fructose-fed rats. HEPATOLOGY 2007;45:778-788.
6. Malik VS, Schulze MB, Hu FB. Intake of sugar-sweetened beverages and weight gain: A systematic review. Am J Clin Nutr 2006;84:274-288.
7. Pereira MA. The possible role of sugar-sweetened beverages in obesity etiology: A review of the evidence. Int J Obesity 2006;30:S28-S36.
8. Helenius M, Hänninen M, Lehtinen SK, Salminen A. Aging-induced up-regulation of nuclear binding activities of oxidative stress responsive NFκB transcription factor in mouse cardiac muscle. J Mol Cell Cardiol 1996;28:487-498.
9. Bradford MM. A rapid sensitive method for the quantitation of microgram quantities of protein utilizing the principles of protein-dye binding. Anal Biochem 1976;72:248-254.
10. Lazarow PB. Assay of peroxisomal β-oxidation of fatty acids. Methods Enzymol 1981;72:315-319.
11. Kudo N, Barr AJ, Barr RL, Desai S, Lopaschuck GD. High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in Malonyl-CoA levels due to an increase in 5′-AMP-activated protein kinase inhibition of acetyl-coa carboxylase. J Biol Chem 1995;270: 17513-17520.
12. Coll T, Jové M, Rodríguez-Calvo R, Eyre E, Palomer X, Sánchez RM, et al. Palmitate-mediated downregulation of peroxisome proliferator-activated receptor-gamma coactivator 1alpha in skeletal muscle cells involves MEK1/2 and nuclear factor-kappaB activation. Diabetes 2006;55:2779-2787.
13. Roglans N, Sanguino E, Peris C, Alegret M, Vázquez M, Adzet T, et al. Atorvastatin treatment induced peroxisome proliferator-activated receptor α expression and decreased plasma nonesterified fatty acids and liver triglyceride in fructose-fed rats. J Pharmacol Exp Ther 2002;302:232-239.
14. Cabrero A, Alegret M, Sánchez RM, Laguna JC, Vázquez-Carrera M. Increased reactive oxygen species production down-regulates peroxisome proliferator-activated α pathway in C2C12 skeletal muscle cells. J Biol Chem 2002;277:10100-10107.
15. Planavila A, Laguna JC, Vázquez-Carrera M. Nuclear Factor kappa B activation leads to down regulation of fatty acid oxidation during cardiac hypertrophy. J Biol Chem 2005;280:17464-17471.
16. Yu X, McCorkle S, Wang M, Lee Y, Saha AK, Unger RH, et al. Leptino-mimetic effects of the AMP kinase activator AICAR in leptin-resistant rats: Prevention of diabetes and ectopic lipid deposition. Diabetologia 2004;47: 2012-2021.
17. Andreelli F, Foretz M, Knauf C, Cani PD, Perrin C, Iglesias MA, et al. Liver adenosine monophosphate-activated kinase-α2 catalytic subunit is a key target for the control of hepatic glucose production by adiponectin and leptin but not insulin. Endocrinology 2006;147:2432-2441.
18. Sriwijitkamol A, Ivy JL, Christ-Roberts C, DeFronzo RA, Mandarino LJ, Musi N. LKB1-AMPK signaling in muscle form obese insulin-resistant Zucker rats and effects of training. Am J Physiol Endocrinol Metabol 2006;290:E925-E932.
19. Alessi DR, Sakamoto K, Bayascas JR. LKB1-Dependent signaling pathways. Annu Rev Biochem 2006;75:137-163.
20. Frühbeck G. Intracellular signalling pathways activated by leptin. Biochemical J 2006;393:7-20.
21. Banks AS, Davis SM, Bates SH, Myers MG. Activation of downstream signals by the long form of the leptin receptor. J Biol Chem 2000;275: 14563-14572.
22. Howard JK, Flier JS. Attenuation of leptin and insulin signaling by SOCS proteins. Trends Endocrinol Metabol 2006;17:365-371.
23. Qu S, Su D, Altomonte J, Kamagate A, He J, Perdomo G, et al. PPARα mediates the hypolipidemic action of fibrates by antagonizing FoxO1. Am J Physiol Endocrinol Metabol 2007;292:E421-E434.
24. Szanto I, Kahn CR. Selective interaction between leptin and insulin signaling pathways in a hepatic cell line. Proc Natl Acad Sci U S A 2000;97: 2355-2360.
25. Naïmi M, Gautier N, Chaussade C, Valverde AM, Accili D, Van Obberghen E. Nuclear forkhead box O1 controls and integrates key signaling pathways in hepatocytes. Endocrinology 2007;148:2424-2434.
26. Hardie DG. AMP-activated protein kinase as a drug target. Annu Rev Pharmacol Toxicol 2007;47:185-210.
27. Merill, AH Jr. De novo sphingolipid biosynthesis: A necessary, but dangerous, pathway. J Biol Chem 2002;277:25843-25846.
28. Ruvolo PP. Intracellular signal transduction pathways activated by ceramide and its metabolites. Pharmacol Res 2003;47:383-392.
29. Uyeda K, Yamashita H, Kawaguchi T. Carbohydrate responsive element-binding protein (ChREBP): A key regulator of glucose metabolism and fat storage. Biochem Pharmacol 2002;63:2075-2080.
30. Uyeda K, Repa JJ. Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis. Cell Metabol 2006;4:107-110.
31. Towler MC, Hardie DG. AMP-activated protein kinase in the metabolic control and insulin signaling. Circ Res 2007;100:328-341.
32. Lefebvre P, Chinetti G, Fruchart JC, Staels B. Sorting out the roles of PPARα in energy metabolism and vascular homeostasis. J Clin Invest 2006;116:571-580.
33. Lee Y, Yu X, Gonzales F, Mangelsdorf DJ, Wang MY, Richardson C, et al. PPARα is necessary for the lipopenic action of hyperleptinemia on white adipose and liver tissue. Proc Natl Acad Sci U S A 2002; 99:11848-11853.
34. Lee WJ, Kim M, Park H-S, Kim HS, Jeon MJ, Oh KS, et al. AMPK activation increases fatty acid oxidation in skeletal muscle by activating PPARα and PGC-1. Biochem Biophys Res Commun 2006;340:291-295.
35. Atkinson LL, Fischer MA, Lopaschuck GD. Leptin activates cardiac fatty acid oxidation independent of changes in the AMP-activated protein kinase-acetyl-CoA carboxylase-malonyl-CoA axis. J Biol Chem 2002;277: 29424-29430.
36. McGarry JD. Travels with carnitine palmitoyltransferase I: From liver to germ cell with stops in between. Biochem Soc Trans 2001;29:241-245.
37. Bamks AS, Davis SM, Bates SH, Myers MG Jr. Activation of downstream signals by the long form of the leptin receptor. J Biol Chem 2000;275: 14563-14572.
38. 727 phosphorylation and DNA binding. Biochem J 2002;364:875-879.
39. Wu Y, Song P, Xu J, Zhang M, Zou M-H. Activation of protein phosphatase 2A by palmitate inhibits AMP-activated protein kinase. J Biol Chem 2007;282:9777-9788.
40. Ravnskjaer K, Boergesen M, Dalgaard LT, Mandrup S. Glucose-induced repression of PPARα gene expression in pancreatic β-cells involves PP2A activation and AMPK inactivation. J Mol Endocrinol 2006; 36:289-299.
41. Ugi S, Imamura T, Maegawa H, Egawa K, Yoshizaki T, Shi K, et al. Protein phosphatase 2A negatively regulates insulin's metabolic signaling pathway by inhibiting Akt (protein kinase B) activity in 3T3-L1 adipocytes. Mol Cell Biol 2004;24:8778-8789.
42. Mayes PA. Intermediary metabolism of fructose. Am J Clin Nutr 1993; 58(Suppl):754S-765S.
43. Lê K-A, Faeh D, Stettler R, Ith M, Kreis R, Vermathen P, et al. A 4-wk high-fructose diet alters lipid metabolism without affecting insulin sensitivity or ectopic lipids in healthy humans. Am J Clin Nutr 2006;84:1374-1379.
44. Hsieh Y-S, Yang S-F, Chiou H-L, Kuo D-Y. Activation of c-fos/c-jun signaling are involved in the modulation of hypothalamic superoxide dismutase (SOD) and neuropeptide Y (NPY) gene expression in amphetamine-mediated appetite suppression. Toxicol Appl Pharmacol 2006;212: 99-109.